semaglutide medicine names Oral Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Type 2 diabetes: New Ozempic
Description
In conclusion, in people with type 2 diabetes and overweight or obesity, semaglutide reduced UACR relative to placebo, including in patients using RAS inhibitors or SGLT2 inhibitors at baseline
The drug was placed on the list in 2022
Evidence, mechanisms, and recommendations
Afternoon Snack: A handful of edamame (steamed soybeans)
